Volume 10, Issue 1 (3-2022)                   Jorjani Biomed J 2022, 10(1): 41-55 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Poorjam M, mohammadi Z, Jafari S M. Adenosine Receptor Signaling in Diseases with Focus on Cancer. Jorjani Biomed J. 2022; 10 (1) :41-55
URL: http://goums.ac.ir/jorjanijournal/article-1-886-en.html
1- Metabolic disorder research center, Golestan University if Medical Sciences, Gorgan, Iran/Department of Biochemistry and Biophysics, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Golestan University of Metabolic disorder research center, Golestan University if Medical Sciences, Gorgan, Iran/Department of Biochemistry and Biophysics, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran sciences , s.meh.jafari@goums.ac.ir
Abstract:   (718 Views)
Various investigation has shown the magnitude role of adenosine receptors in cancer development. The A1, A2A, A2B, and A3 G-protein-coupled cell surface Adenosine Receptors (ARs) are found to be upregulated in many types of cancers. The adenosine receptor function has been affected by specific ligands such as agonists and/or antagonists regulated cancer (Neoplasms) cells proliferation via signaling pathways. Adenosine not only is an important intermediate metabolite but also acts as the essential ligand of adenosine receptors in physiological and pathological conditions. Furthermore, many studies have shown that adenosine receptors expression has increased in many types of cancer. In this review, we first describe adenosine's role in physiological condition and in cancer development. We further, discuss the type of adenosine receptors, distribution, expression, and their roles in cancer.
Full-Text [PDF 855 kb]   (138 Downloads) |   |   Full-Text (HTML)  (130 Views)  
 The A1, A2A, A2B, and A3 G-protein-coupled cell surface are four Adenosine Receptors subtypes.
 Adenosine receptors have a critical role in diseases pathogenesis such as cancers (neoplasm) development.
 The function of ARs affected by natural and synthetic ligands such as agonists and antagonist.

 
Type of Article: Review Article | Subject: Basic Medical Sciences
Received: 2022/02/1 | Accepted: 2022/02/19 | Published: 2022/03/30

References
1. Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiological reviews. 2018;98(3):1591-625. [view at publisher] [DOI] [PMID] [Google Scholar]
2. Shi Y, Dai Q, Ji B, Huang L, Zhuang X, Mo Y, et al. Electroacupuncture Pretreatment Prevents Cognitive Impairment Induced by Cerebral Ischemia-Reperfusion via Adenosine A1 Receptors in Rats. Frontiers in Aging Neuroscience. 2021:371. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
3. Mannino F, Pallio G, Bitto A, Altavilla D, Minutoli L, Squadrito V, et al. Targeting Adenosine Receptor by Polydeoxyribonucleotide: An Effective Therapeutic Strategy to Induce White-to-Brown Adipose Differentiation and to Curb Obesity. Pharmaceuticals. 2021;14(8):728. [DOI] [PMID] [PMCID] [Google Scholar]
4. Kwon JH, Lee J, Kim J, Jo YH, Kirchner VA, Kim N, et al. HIF‑1α regulates A2B adenosine receptor expression in liver cancer cells. Experimental and therapeutic medicine. 2019;18(6):4231-40. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
5. Jackson EK, Dubey RK. Role of the extracellular cAMP-adenosine pathway in renal physiology. American Journal of Physiology-Renal Physiology. 2001;281(4):F597-F612. [view at publisher] [DOI] [PMID] [Google Scholar]
6. Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chemical reviews. 2008;108(1):238-63. [view at publisher] [DOI] [PMID] [Google Scholar]
7. Fredholm BB. Adenosine receptors as drug targets. Experimental cell research. 2010;316(8):1284-8. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
8. Camici M, Garcia-Gil M, Tozzi MG. The inside story of adenosine. International journal of molecular sciences. 2018;19(3):784. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
9. Jafari SM. Role of Adenosine receptor in lung cancer. Jorjani Biomedicine Journal. 2020;8:1-3. [view at publisher] [Google Scholar]
10. Chen J-F, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nature reviews Drug discovery. 2013;12(4):265-86. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
11. Baldwin JM. Structure and function of receptors coupled to G proteins. Current opinion in cell biology. 1994;6(2):180-90. [view at publisher] [DOI] [Google Scholar]
12. Mori A, Cross B, Uchida S, Kerrick Walker J, Ristuccia R. How Are Adenosine and Adenosine A2A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis? Biomedicines. 2021;9(8):1027. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
13. dos Santos-Rodrigues A, Grañé-Boladeras N, Bicket A, Coe IR. Nucleoside transporters in the purinome. Neurochemistry international. 2014;73:229-37. [view at publisher] [DOI] [PMID] [Google Scholar]
14. Hoshino T, Yamada K, Masuoka K, Tsuboi I, Itoh K, Nonaka K, et al. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Research and clinical practice. 1994;25(2):97-102. [view at publisher] [DOI] [Google Scholar]
15. Stockwell J, Jakova E, Cayabyab FS. Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration. Molecules. 2017;22(4):676. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
16. Dahl G. ATP release through pannexon channels. Philosophical Transactions of the Royal Society B: Biological Sciences. 2015;370(1672):20140191. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
17. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets. Immunological reviews. 2017;276(1):121-44. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
18. Yang J, Liao X, Yu J, Zhou P. Role of CD73 in disease: promising prognostic indicator and therapeutic target. Current medicinal chemistry. 2018;25(19):2260-71. [view at publisher] [DOI] [PMID] [Google Scholar]
19. Jackson EK, Boison D, Schwarzschild MA, Kochanek PM. Purines: forgotten mediators in traumatic brain injury. Journal of neurochemistry. 2016;137(2):142-53. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
20. Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. Journal of clinical immunology. 2017;37(7):626-37. [view at publisher] [DOI] [PMID] [Google Scholar]
21. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. The Journal of Immunology. 2012;188(1):198-205. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
22. Oyarzun C, Garrido W, Alarcon S, Yanez A, Sobrevia L, Quezada C, et al. Adenosine contribution to normal renal physiology and chronic kidney disease. Molecular aspects of medicine. 2017;55:75-89. [view at publisher] [DOI] [PMID] [Google Scholar]
23. Ng MSY, Tung J-P, Fraser JF. Platelet storage lesions: what more do we know now? Transfusion medicine reviews. 2018;32(3):144-54. [view at publisher] [DOI] [PMID] [Google Scholar]
24. Nguyen MD, Venton BJ. Fast-scan cyclic voltammetry for the characterization of rapid adenosine release. Computational and structural biotechnology journal. 2015;13:47-54. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
25. Hoiland RL, Bain AR, Rieger MG, Bailey DM, Ainslie PN. Hypoxemia, oxygen content, and the regulation of cerebral blood flow. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2016;310(5):R398-R413. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
26. Burnstock G, Pelleg A. Cardiac purinergic signalling in health and disease. Purinergic signalling. 2015;11(1):1-46. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
27. Spina D, Page C. Xanthines and phosphodiesterase inhibitors. Pharmacology and Therapeutics of Asthma and COPD. 2016:63-91. [view at publisher] [DOI] [PMID] [Google Scholar]
28. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461(7261):282-6. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
29. Ballarin M, Fredholm B, Ambrosio S, Mahy N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta physiologica Scandinavica. 1991;142(1):97-103. [view at publisher] [DOI] [PMID] [Google Scholar]
30. Zetterström T, Vernet L, Ungerstedt U, Tossman U, Jonzon B, Fredholm B. Purine levels in the intact rat brain. Studies with an implanted perfused hollow fibre. Neuroscience letters. 1982;29(2):111-5. [view at publisher] [DOI] [Google Scholar]
31. Pedata F, Corsi C, Melani A, Bordoni F, Latini S. Adenosine extracellular brain concentrations and role of A2A receptors in ischemia. Annals of the New York Academy of Sciences. 2001;939(1):74-84. [view at publisher] [DOI] [PMID] [Google Scholar]
32. Andiné P, Rudolphi KA, Fredholm BB, Hagberg H. Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia. British journal of pharmacology. 1990;100(4):814-8. [DOI] [PMID] [PMCID] [Google Scholar]
33. Fastbom J, Ungerstedt U, Rudolphi K, Fredholm BB. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain research. 1990;516(2):248-56. [view at publisher] [DOI] [Google Scholar]
34. Eckle T, Koeppen M, Eltzschig HK. Role of extracellular adenosine in acute lung injury. Physiology. 2009;24(5):298-306. [view at publisher] [DOI] [PMID] [Google Scholar]
35. Semenza GL. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2011;1813(7):1263-8. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
36. Van Welden S, Selfridge AC, Hindryckx P. Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nature Reviews Gastroenterology & Hepatology. 2017;14(10):596-611. [view at publisher] [DOI] [PMID] [Google Scholar]
37. Kumar V, Gabrilovich DI. Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 2014;143(4):512-9. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
38. Howell NJ, Tennant DA. The role of HIFs in ischemia-reperfusion injury. Hypoxia. 2014;2:107. [DOI] [PMID] [PMCID] [Google Scholar]
39. Qiang Q, Manalo JM, Sun H, Zhang Y, Song A, Wen AQ, et al. Erythrocyte adenosine A2B receptor prevents cognitive and auditory dysfunction by promoting hypoxic and metabolic reprogramming. PLoS biology. 2021;19(6):e3001239. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
40. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. Nature Reviews Immunology. 2005;5(9):712-21. [view at publisher] [DOI] [PMID] [Google Scholar]
41. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends in molecular medicine. 2013;19(6):345-54. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
42. Le T-TT, Berg NK, Harting MT, Li X, Eltzschig HK, Yuan X. Purinergic signaling in pulmonary inflammation. Frontiers in immunology. 2019;10:1633. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
43. Bowser JL, Lee JW, Yuan X, Eltzschig HK. The hypoxia-adenosine link during inflammation. Journal of Applied Physiology. 2017;123(5):1303-20. [view at publisher] [DOI] [PMID] [PMCID] [ISI]
44. Arab S, Hasannejad F. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach. Clinical and Translational Oncology. 2021:1-15. [view at publisher] [DOI] [PMID] [Google Scholar]
45. Burnstock G, Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta physiologica. 2009;195(4):415-47. [view at publisher] [DOI] [PMID] [Google Scholar]
46. Ciccarelli R, Ballerini P, Sabatino G, Rathbone M, D'Onofrio M, Caciagli F, et al. Involvement of astrocytes in purine-mediated reparative processes in the brain. International Journal of Developmental Neuroscience. 2001;19(4):395-414. [view at publisher] [DOI] [Google Scholar]
47. Giuliani AL, Sarti AC, Di Virgilio F. Extracellular nucleotides and nucleosides as signalling molecules. Immunology letters. 2019;205:16-24. [view at publisher] [DOI] [PMID] [Google Scholar]
48. Martin GS. Cell signaling and cancer. Cancer cell. 2003;4(3):167-74. [DOI]
49. Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J. International :union: of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological reviews. 2001;53(4):527-52. [view at publisher] [Google Scholar]
50. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacological reviews. 1998;50(3):413-92. [Google Scholar]
51. Burnstock G, Verkhratsky A. Receptors for purines and pyrimidines. Purinergic Signalling and the Nervous System: Springer; 2012. p. 119-244. [view at publisher] [DOI] [Google Scholar]
52. Khakh B, Burnstock G, Kennedy C, King B, North R, Seguela P, et al. Current status of the nomenclature and properties of P2X receptors and their subunits. International :union: of Pharmacology. XXIV. Pharmacol Rev. 2001;53:107-18. [view at publisher] [Google Scholar]
53. Li J-m, Fenton RA, Wheeler HB, Powell CC, Peyton BD, Cutler BS, et al. Adenosine A2aReceptors Increase Arterial Endothelial Cell Nitric Oxide. Journal of Surgical Research. 1998;80(2):357-64. [view at publisher] [DOI] [PMID] [Google Scholar]
54. Jafari S, Joshaghani H, Panjehpour M, Aghaei M, Zargar Balajam N. Apoptosis and cell cycle regulatory effects of adenosine by modulation of GLI‐1 and ERK 1/2 pathways in CD 44+ and CD 24− breast cancer stem cells. Cell proliferation. 2017;50(4):e12345. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
55. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's archives of pharmacology. 2000;362(4-5):364-74. [view at publisher] [DOI] [PMID] [Google Scholar]
56. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Annals of the New York academy of sciences. 1999;890(1):79-92. [view at publisher] [DOI] [PMID] [Google Scholar]
57. Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Adenosine Receptors in Health and Disease. 2009:161-88. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
58. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Current topics in medicinal chemistry. 2003;3(4):369-85. [view at publisher] [DOI] [PMID] [Google Scholar]
59. Visser SS, Theron AJ, Ramafi G, Ker JA, Anderson R. Apparent involvement of the A2A subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils. Biochemical pharmacology. 2000;60(7):993-9. [view at publisher] [DOI] [Google Scholar]
60. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2011;1808(5):1400-12. [DOI] [PMID]
61. Tian T, Zhou Y, Feng X, Ye S, Wang H, Wu W, et al. MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting. Scientific Reports. 2016;6(1):30824. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
62. Sun Y, Huang P. Adenosine A2B receptor: from cell biology to human diseases. Frontiers in chemistry. 2016;4:37. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
63. Zheng Z, Hu H, Tong Y, Hu Z, Cao S, Shan C, et al. MiR-27b regulates podocyte survival through targeting adenosine receptor 2B in podocytes from non-human primate. Cell death & disease. 2018;9(11):1133. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
64. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-α production in the human newborn. The Journal of Immunology. 2006;177(3):1956-66. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
65. Shi C, Szczesniak A, Mao L, Jollimore C, Coca-Prados M, Hung O, et al. A3 adenosine and CB1 receptors activate a PKC-sensitive Cl− current in human nonpigmented ciliary epithelial cells via a Gβγ-coupled MAPK signaling pathway. British journal of pharmacology. 2003;139(3):475. [DOI] [PMID] [PMCID] [Google Scholar]
66. Mitchell CH, Peterson-Yantorno K, Carré DA, McGlinn AM, Coca-Prados M, Stone RA, et al. A3 adenosine receptors regulate Cl− channels of nonpigmented ciliary epithelial cells. American Journal of Physiology-Cell Physiology. 1999;276(3):C659-C66. [view at publisher] [DOI] [PMID] [Google Scholar]
67. Karl MO, Fleischhauer JC, Stamer WD, Peterson-Yantorno K, Mitchell CH, Stone RA, et al. Differential P1-purinergic modulation of human Schlemm's canal inner-wall cells. American Journal of Physiology-Cell Physiology. 2005;288(4):C784-C94. [view at publisher] [DOI] [PMID] [Google Scholar]
68. Zhao Z, Yaar R, Ladd D, Cataldo LM, Ravid K. Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. Microvascular research. 2002;63(1):61-9. [view at publisher] [DOI] [PMID] [Google Scholar]
69. Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, et al. Activation of murine lung mast cells by the adenosine A3 receptor. The Journal of Immunology. 2003;171(1):338-45. [view at publisher] [DOI] [PMID] [Google Scholar]
70. Rorke S, Holgate ST. Targeting Adenosine Receptors. American Journal of Respiratory Medicine. 2002;1(2):99-105. [view at publisher] [DOI] [PMID] [Google Scholar]
71. Fishman P, Bar-Yehuda S. Pharmacology and therapeutic applications of A3 receptor subtype. Current topics in medicinal chemistry. 2003;3(4):463-9. [view at publisher] [DOI] [PMID] [Google Scholar]
72. Fishman P, Bar-Yehuda S, Madi L, Cohn I. A3 adenosine receptor as a target for cancer therapy. Anti-cancer drugs. 2002;13(5):437-43. [view at publisher] [DOI] [PMID] [Google Scholar]
73. Jacobson K, Hoffmann C, Cattabeni F, Abbracchio M. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis. 1999;4(3):197-211. [view at publisher] [DOI] [PMID] [Google Scholar]
74. Sandhu H, Cooper S, Hussain A, Mee C, Maddock H. Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation. European journal of pharmacology. 2017;814:95-105. [view at publisher] [DOI] [PMID] [Google Scholar]
75. Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nature Reviews Cancer. 2013;13(12):842-57. [view at publisher] [DOI] [PMID] [Google Scholar]
76. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer discovery. 2014;4(8):879-88. [view at publisher] [DOI] [PMID] [Google Scholar]
77. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279-90. [view at publisher] [DOI] [PMID] [Google Scholar]
78. Vijayan D, Young A, Teng MW, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nature Reviews Cancer. 2017;17(12):709-24. https://doi.org/10.1038/nrc.2017.86 [view at publisher] [DOI] [PMID] [Google Scholar]
79. Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, et al. Adenosine A2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells. Proceedings of the National Academy of Sciences. 2009;106(26):10684-9. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
80. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Current opinion in pharmacology. 2016;29:7-16. [view at publisher] [DOI] [PMID] [Google Scholar]
81. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circulation research. 2005;97(8):837-44. [view at publisher] [DOI] [PMID] [Google Scholar]
82. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension. 1998;31(1):516-21. [view at publisher] [DOI] [PMID] [Google Scholar]
83. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer. 2002;94(10):2766-92. [view at publisher] [DOI] [PMID] [Google Scholar]
84. El-Darahali A, Fawcett H, Mader JS, Conrad DM, Hoskin DW. Adenosine-induced apoptosis in EL-4 thymoma cells is caspase-independent and mediated through a non-classical adenosine receptor. Experimental and molecular pathology. 2005;79(3):249-58. [view at publisher] [DOI] [PMID] [Google Scholar]
85. Gessi S, Cattabriga E, Avitabile A, Lanza G, Cavazzini L, Bianchi N, et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clinical Cancer Research. 2004;10(17):5895-901. [view at publisher] [DOI] [PMID] [Google Scholar]
86. Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2008;1783(2):297-311. [view at publisher] [DOI] [PMID] [Google Scholar]
87. Grant MB, Tarnuzzer RW, Caballero S, Ozeck MJ, Davis MI, Spoerri PE, et al. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circulation Research. 1999;85(8):699-706. [view at publisher] [DOI] [PMID] [Google Scholar]
88. Hashemi M, Karami‐Tehrani F, Ghavami S, Maddika S, Los M. Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor‐positive and‐negative human breast cancer cells via the intrinsic pathway. Cell proliferation. 2005;38(5):269-85. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
89. Hua X, Chason KD, Jania C, Acosta T, Ledent C, Tilley SL. Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation. Journal of Pharmacology and Experimental Therapeutics. 2013;344(2):426-35. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
90. Jajoo S, Mukherjea D, Watabe K, Ramkumar V. Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia. 2009;11(11):1132-IN5. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
91. Safarzadeh E, Jadidi-Niaragh F, Motallebnezhad M, Yousefi M. The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. Inflammation Research. 2016;65(7):511-20. [view at publisher] [DOI] [PMID] [Google Scholar]
92. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacology & therapeutics. 2003;100(1):31-48. [view at publisher] [DOI] [Google Scholar]
93. Khoo H-E, Ho C-L, Chhatwal VJ, Chan ST, Ngoi S-S, Moochhala SM. Differential expression of adenosine A1 receptors in colorectal cancer and related mucosa. Cancer letters. 1996;106(1):17-21. [view at publisher] [DOI] [Google Scholar]
94. Ohana G, Bar-Yehuda S, Arich A, Madi L, Dreznick Z, Rath-Wolfson L, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. British journal of cancer. 2003;89(8):1552-8. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
95. Xiang H-j, Liu Z-c, Wang D-s, Chen Y, Yang Y-l, Dou K-f. Adenosine A2b receptor is highly expressed in human hepatocellular carcinoma. Hepatology research. 2006;36(1):56-60. [view at publisher] [DOI] [PMID] [Google Scholar]
96. Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, et al. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer biology & therapy. 2008;7(2):278-84. [view at publisher] [DOI] [PMID] [Google Scholar]
97. Ma D-F, Kondo T, Nakazawa T, Niu D-F, Mochizuki K, Kawasaki T, et al. Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Human pathology. 2010;41(11):1550-7. [view at publisher] [DOI] [PMID] [Google Scholar]
98. Tajadini M, Panjehpour M, Javanmard SH. Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes. Advanced biomedical research. 2014;3. [DOI] [PMID] [PMCID] [Google Scholar]
99. Mousavi S, Panjehpour M, Izadpanahi MH, Aghaei M. Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues. The Prostate. 2015;75(7):735-47. [view at publisher] [DOI] [PMID] [Google Scholar]
100. Hajiahmadi S, Panjehpour M, Aghaei M, Mousavi S. Molecular expression of adenosine receptors in OVCAR-3, Caov-4 and SKOV-3 human ovarian cancer cell lines. Research in pharmaceutical sciences. 2015;10(1):43. [Google Scholar]
101. Zhou Y, Tong L, Chu X, Deng F, Tang J, Tang Y, et al. The adenosine A1 receptor antagonist DPCPX inhibits tumor progression via the ERK/JNK pathway in renal cell carcinoma. Cellular Physiology and Biochemistry. 2017;43(2):733-42. [view at publisher] [DOI] [PMID] [Google Scholar]
102. Wu Z, Yang L, Shi L, Song H, Shi P, Yang T, et al. Prognostic impact of adenosine receptor 2 (A2aR) and programmed cell death ligand 1 (PD-L1) expression in colorectal cancer. BioMed research international. 2019;2019. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
103. Meng Z, Yutong S, Liu J, Zhang J, Zheng Z, Wang Z, et al. Expression and Gene Regulation Network of Adenosine Receptor A2B in Lung Adenocarcinoma: A Potential Diagnostic and Prognostic Biomarker. Frontiers in molecular biosciences. 2021;8:622. [DOI] [PMID] [PMCID] [Google Scholar]
104. Kasama H, Sakamoto Y, Kasamatsu A, Okamoto A, Koyama T, Minakawa Y, et al. Adenosine A2b receptor promotes progression of human oral cancer. BMC cancer. 2015;15(1):1-12. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
105. Yasuda Y, Saito M, Yamamura T, Yaguchi T, Nishizaki T. Extracellular adenosine induces apoptosis in Caco-2 human colonic cancer cells by activating caspase-9/-3 via A 2a adenosine receptors. Journal of gastroenterology. 2009;44(1):56-65. [view at publisher] [DOI] [PMID] [Google Scholar]
106. Etique N, Grillier-Vuissoz I, Lecomte J, Flament S. Crosstalk between adenosine receptor (A2A isoform) and ERα mediates ethanol action in MCF-7 breast cancer cells. Oncology reports. 2009;21(4):977-81. [view at publisher] [DOI] [PMID] [Google Scholar]
107. Joshaghani HR, Jafari SM, Aghaei M, Panjehpour M, Abedi H. A3 adenosine receptor agonist induce G1 cell cycle arrest via Cyclin D and cyclin-dependent kinase 4 pathways in OVCAR-3 and Caov-4 cell lines. Journal of cancer research and therapeutics. 2017;13(1):107. [view at publisher] [DOI] [PMID] [Google Scholar]
108. Jafari SM, Panjehpour M, Aghaei M, Joshaghani HR, Enderami SE. A3 adenosine receptor agonist inhibited survival of breast cancer stem cells via GLI‐1 and ERK1/2 pathway. Journal of cellular biochemistry. 2017;118(9):2909-20. [view at publisher] [DOI] [PMID] [Google Scholar]
109. Jafari SM, Joshaghani HR, Panjehpour M, Aghaei M. A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation. Cellular Oncology. 2018;41(1):61-72. [view at publisher] [DOI] [PMID] [Google Scholar]
110. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International :union: of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacological reviews. 2011;63(1):1-34. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
111. Saito M, Yaguchi T, Yasuda Y, Nakano T, Nishizaki T. Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A1 adenosine receptors. Cancer letters. 2010;290(2):211-5. [view at publisher] [DOI] [PMID] [Google Scholar]
112. Bozorov K, Nie LF, Zhao J, Aisa HA. 2-Aminothiophene scaffolds: Diverse biological and pharmacological attributes in medicinal chemistry. European journal of medicinal chemistry. 2017;140:465-93. [view at publisher] [DOI] [PMID] [Google Scholar]
113. Lohse MJ, Klotz K-N, Lindenborn-Fotinos J, Reddington M, Schwabe U, Olsson RA. 8-Cyclopentyl-1, 3-dipropylxanthine (DPCPX)-a selective high affinity antagonist radioligand for A 1 adenosine receptors. Naunyn-Schmiedeberg's archives of pharmacology. 1987;336(2):204-10. [view at publisher] [DOI] [PMID] [Google Scholar]
114. Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, et al. Binding of the A 1-selective adenosine antagonist 8-cyclopentyl-1, 3-dipropylxanthine to rat brain membranes. Naunyn-Schmiedeberg's archives of pharmacology. 1987;335(1):59-63. [view at publisher] [DOI] [PMID] [Google Scholar]
115. Fredholm BB, Cunha RA, Svenningsson P. Pharmacology of adenosine A2A receptors and therapeutic applications. Current topics in medicinal chemistry. 2003;3(4):413-26. [view at publisher] [DOI] [PMID] [Google Scholar]
116. Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz K-N. Medicinal chemistry and pharmacology of A2B adenosine receptors. Current topics in medicinal chemistry. 2003;3(4):427-43. [view at publisher] [DOI] [PMID] [Google Scholar]
117. Feoktistov I, Biaggioni I. Role of adenosine A2B receptors in inflammation. Advances in pharmacology. 2011;61:115-44. [DOI] [PMID] [PMCID]
118. Gao Z-G, Blaustein JB, Gross AS, Melman N, Jacobson KA. N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochemical pharmacology. 2003;65(10):1675-84. [DOI] [Google Scholar]
119. Gao Z-G, Kim SG, Soltysiak KA, Melman N, IJzerman AP, Jacobson KA. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Molecular pharmacology. 2002;62(1):81-9. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb